---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 749
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in high-risk infants. The TxGNN model assigns a very high score (99.94%) to **Benign Neoplasm of Tongue** as a repurposing candidate, but this is currently supported by **zero clinical trials** and **zero publications**, and the model's own mechanistic rationale states no biologically plausible link exists between an anti-RSV antibody and this indication.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV (Respiratory Syncytial Virus) prophylaxis in high-risk infants (based on known drug identity — not covered by Singapore regulatory data, as the product is unmarketed here) |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Palivizumab is a humanized monoclonal antibody directed against the F (fusion) glycoprotein of respiratory syncytial virus; its only established biological activity is viral neutralization, and it has no known interaction with oncogenic pathways (e.g., EGFR, VEGF, immune checkpoints) or with any tissue-specific process relevant to tongue neoplasia.

There is no known pharmacological, anatomical, or pathway-level relationship between RSV prophylaxis and benign tongue neoplasm. The evidence pack's own repurposing rationale is explicit on this point: it describes the high TxGNN score as most likely reflecting proximity between nodes in the knowledge graph (e.g., shared upper-respiratory/head-and-neck anatomical associations) rather than a genuine pharmacological signal.

This same pattern repeats across all ten top-ranked predictions for this drug in the evidence pack (epiglottis neoplasm, cervical neuroblastoma, hypopharynx/floor-of-mouth neoplasms, testicular tumor, cystic neoplasm, schwannoma, mesenchymoma, thyroglossal duct cyst) — all score near 99.94%, all are rated L5/Hold, and all carry rationale text stating no credible mechanistic link exists. This clustering suggests a systemic graph-embedding artifact for this drug rather than an isolated false positive, and should be treated as a signal to investigate the underlying node embeddings rather than a genuine repurposing lead.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Palivizumab is not currently marketed in Singapore (0 registered licenses). No local authorization, product, or approved-indication data is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN score is high, but there is no supporting clinical trial or literature evidence, and the model's own mechanistic rationale concludes the signal is not biologically plausible — most likely a knowledge-graph proximity artifact rather than a real repurposing opportunity. The drug is also not marketed in Singapore, so there is no local regulatory or safety data to build a submission on.

**To proceed, the following is needed:**
- Formal DrugBank/label-sourced mechanism of action (MOA) data (currently a data gap)
- TFDA/manufacturer package insert warnings and contraindications (currently a data gap)
- Independent biological rationale (e.g., target expression data in tongue/oral tissue) before this candidate is escalated beyond S0
- If pursued at all, this should be treated as a low-priority signal requiring dedicated mechanistic investigation, not a standard evidence-collection cycle
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

